Myriad Genetics Downgraded to Neutral at Ned Davis Research (MYGN)
Myriad Genetics (NASDAQ:MYGN) was downgraded by Ned Davis Research from a “buy” rating to a “neutral” rating in a research note issued on Monday, American Banking & Market News reports.
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Myriad Genetics (NASDAQ:MYGN) in a research note to investors on Thursday, September 19th. They now have a $27.00 price target on the stock. Finally, analysts at Cowen and Company downgraded shares of Myriad Genetics (NASDAQ:MYGN) from an “outperform” rating to a “market perform” rating in a research note to investors on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $34.23.
Myriad Genetics (NASDAQ:MYGN) traded down 0.66% during mid-day trading on Monday, hitting $25.75. The stock had a trading volume of 383,087 shares. Myriad Genetics has a 52 week low of $24.08 and a 52 week high of $38.27. The stock has a 50-day moving average of $27.05 and a 200-day moving average of $28.42. The company has a market cap of $2.071 billion and a price-to-earnings ratio of 14.64.
Myriad Genetics (NASDAQ:MYGN) last released its earnings data on Tuesday, August 13th. The company reported $0.53 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.09. The company had revenue of $174.10 million for the quarter, compared to the consensus estimate of $159.87 million. During the same quarter last year, the company posted $0.34 earnings per share. Myriad Genetics’s revenue was up 30.9% compared to the same quarter last year. Analysts expect that Myriad Genetics will post $1.91 EPS for the current fiscal year.
Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.